Compare AENT & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AENT | CRDL |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Durable Goods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.1M | 226.6M |
| IPO Year | 2020 | 2017 |
| Metric | AENT | CRDL |
|---|---|---|
| Price | $4.40 | $0.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $9.00 | $8.55 |
| AVG Volume (30 Days) | 21.9K | ★ 764.3K |
| Earning Date | 11-12-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $2,700,000.00 | N/A |
| Revenue This Year | $2.26 | N/A |
| Revenue Next Year | $2.56 | N/A |
| P/E Ratio | $16.88 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.28 | $0.88 |
| 52 Week High | $8.80 | $2.34 |
| Indicator | AENT | CRDL |
|---|---|---|
| Relative Strength Index (RSI) | 45.24 | 28.32 |
| Support Level | $4.32 | $0.94 |
| Resistance Level | $5.19 | $1.10 |
| Average True Range (ATR) | 0.29 | 0.06 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 24.75 | 20.33 |
Alliance Entertainment Holding Corp is a distributor and retailer of physical entertainment and collectible products, including vinyl records, CDs, DVDs, Blu-rays, video games, electronics, and licensed fan merchandise. The company connects content creators with retailers, following its multi-channel distribution model across several countries. Its business operations are supported by a diverse portfolio of direct-to-consumer brands, including Critics' Choice Video, Collectors' Choice Music, Movies Unlimited, DeepDiscount, PopMarket, Blowitoutahere, Fulfillment Express, ImportCDs, GamerCandy, and WowHD. Alliance also provides third-party logistics (3PL) and drop-ship fulfillment capabilities for brands and retailers.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.